Overview

A Cumulative Dose Study to Evaluate the Safety and Efficacy of Albuterol in a Dry Powder Inhaler and an HFA MDI (Hydrofluoroalkane Metered Dose Inhaler)

Status:
Completed

Trial end date:
2010-06-01

Target enrollment:

Participant gender:

Summary

The study will measure the improvement in lung function in subjects with asthma after inhaling from two inhalers, Albuterol in a dry powder inhaler and albuterol in an HFA (hydrofluoroalkane), metered dose inhaler.

Phase:

Phase 1

Details

Lead Sponsor:

Teva Branded Pharmaceutical Products R&D, Inc.
Teva Branded Pharmaceutical Products, R&D Inc.

Collaborator:

Parexel

Treatments:

Albuterol